Novartis Enters $5 Billion Licensing Deal with Argo Therapeutics for RNA-Based ANGPTL3 Drugs

Novartis has entered into a licensing agreement with China-based biotechnology company Argo Therapeutics, a deal that could potentially exceed $5 billion in value. The collaboration focuses on the development of RNA-based drugs targeting ANGPTL3, a protein associated with cardiovascular and metabolic diseases. This marks one of several partnerships Novartis has formed with Chinese biotech firms in recent years as part of its broader strategy to expand its pipeline through external innovation.

Under the terms of the agreement, Novartis will gain exclusive global rights to develop and commercialize Argo’s RNA-targeting therapies for ANGPTL3. In return, Argo will receive an upfront payment from Novartis, along with milestone payments tied to clinical, regulatory, and commercial achievements. Royalties on future product sales are also included in the deal structure. This partnership reflects ongoing interest in RNA-based therapeutics as a promising area for addressing unmet medical needs in complex diseases.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: September 3, 2025

Author

Mark Chiang